Back to catalogue
№ 218 33 filings · 2021-05-25 → 2026-05-19

IXICO PLC

IXI
Health Care Share price 7.75p Market cap £17m Overall fit 480 /1000

Partial fit for the strategy: high operating leverage and a discounted valuation are clearly present, but the AI exposure is moderate (specialist AI-imaging vendor, not picks-and-shovels) and the loss history plus 4.5x share-count dilution in 18 months limit downside protection.

Fair value range 11p–21p Mid case · £32m
Absolute upside +90% vs current market cap
Conviction 3/5 confidence in undervalued call
Supports the call
  • clean AIM disclosure with detailed order book/cash bridges
  • £18.1m order book covers 95% of FY26 revenue expectation
  • EV of ~£8m vs £6.5m revenue and £11m net cash is hard to argue with
Limits the call
  • loss-making business — fair value rests on revenue-multiple assumption rather than DCF
  • TechBio pivot is binary — success doubles the multiple, failure leaves it as sub-scale CRO
Methodology

EV/Sales sum-of-parts plus net cash

In one line · bull case

A genuine AI-imaging vertical SaaS / CRO trading at ~1x EV/sales with £11m net cash and high operating leverage — buying optionality on a TechBio re-rating roughly free.

In one line · biggest risk

The TechBio licensing pivot fails to gain traction, the business remains a sub-scale loss-making iCRO, and another dilutive raise becomes necessary within 18-24 months.

Drivers
AI beneficiary 55 /100
Genuine AI-in-medical-imaging with paying biopharma customers and Medidata partnership, but a small specialist vertical rather than a clear AI-spend recipient.
Operating leverage 78 /100
Fixed-cost software platform: H1 26 revenue +23% drove gross margin from 49.6% to 53.2%, with management explicitly citing 'relatively fixed nature of costs of delivery'.
Earnings vs expectations 58 /100
Mixed historical record (2021/2022 trial-cessation shocks, March 2024 profit warning) offset by a consistent run of beats under new CEO Goorden through FY25 and H1 26.
Growth momentum 70 /100
H1 26 revenue +23% YoY, order book +38% YoY — clear acceleration after FY24 trough.
Moat 45 /100
Narrow but real: 20-year neuroscience-only focus, 1,250 imaging-centre network, 350k+ scans processed, validated AI in HD; but small relative to ThermoFisher/Clario.
Earnings quality 55 /100
Generally clean IFRS reporting but H1 26 included £0.4m platform impairment and an R&D tax credit reclassification — both flagged transparently.
Management quality 55 /100
New CEO (joined late 2024) has executed return-to-growth and consummated value-validating Medidata deal; capital raises priced at increasingly low levels are a concern.
Cyclicality 45 /100
Limited — biopharma R&D spend is somewhat cyclical with funding cycles but neurological trial pipelines are structurally growing.
Leverage 10 /100
Net cash of ~£11m post-raise vs £18.9m market cap; no debt. Fortress balance sheet on this metric.
Value-trap signals · 4
  • two equity raises in 18 months with ~4.5x share-count expansion (48m → 218m)
  • loss-making for the full period under review except FY22
  • two prior client-trial-cessation shocks (March 2021, January 2022) materially descoped the order book
  • TechBio strategy unproven — the implied multiple re-rating depends on a licensing pivot that may not deliver

IXICO PLC (AIM: IXI) — Investment Research Note

Executive summary

IXICO is a UK-listed neuroscience imaging Contract Research Organisation (iCRO) that uses its proprietary AI-driven IXI™ platform to analyse brain scans for biopharma clients running neurological drug trials (Alzheimer's, Parkinson's, Huntington's). The five-year trajectory shows a business that has stabilised after twin shocks (large HD trial cancellations in 2021 and 2022 wiped revenue/order book) and returned to growth (+13% FY25, +23% H1 26), with management now pivoting via a "TechBio" strategy to platform-license its IXI™ technology to larger CROs (Medidata partnership signed March 2026). The single most important valuation point today is that the post-money market cap of £18.9m vs ~£11m net cash leaves an implied enterprise value of just ~£8m for a £6.5m-revenue, 53%-gross-margin specialist platform business with a £18.1m contracted order book.

Fair value estimate

Methodology: Sum-of-parts using EV/Sales multiple on the core iCRO business plus net cash. Given persistent EBITDA losses, DCF is not robust; given micro-cap status and a stated management "TechBio" thesis (which they argue should attract 4–7x revenue vs. 1–3x for CROs), a revenue-multiple frame is appropriate.

Key assumptions:

  • Net cash post-raise: ~£11m (£1.7m at 31 Mar 26 + £9.4m net April 2026 raise, 2026-05-19 H1)
  • FY26E revenue ~£7.5m (15% guided growth on £6.5m FY25, 2026-05-19 H1)
  • FY27E revenue ~£8.5m (continued growth, conservative)
  • Conservative case: 1.5x FY27E revenue (typical CRO multiple low end)
  • Central case: 2.5x FY27E revenue (justified by scientific niche, AI platform, 53%+ gross margin trajectory)
  • Bull case: 4.0x FY27E revenue (if TechBio licensing model gains traction)

Fair value range per share (218m shares):

  • Low: (1.5 × £8.5m) + £11m = £23.75m → ~10.9p
  • Mid: (2.5 × £8.5m) + £11m = £32.25m → ~14.8p
  • High: (4.0 × £8.5m) + £11m = £45m → ~20.6p

Implied market cap range: £23.75m – £45m Current market cap: £18.9m Upside to mid-point: +71% (vs. 8.65p current price to 14.8p mid) Upside range: +26% (low) to +138% (bull)

Sector context

  • Sector: Health Care (Health Care Services / Pharma Services sub-sector). Specifically a niche neuroimaging iCRO.
  • Quality/growth/leverage profile: Below typical large-cap CRO peers in scale and profitability (loss-making, sub-scale), in-line on growth (mid-teens %), and ahead on balance sheet (net cash, no debt) following the April 2026 raise.
  • Listed peers: Difficult to name pure neuroimaging CROs publicly. Closest comparables: Clario (private, ThermoFisher acquisition reference, 2026-03-31 placing circular); Perspectum (private); broader CRO peers ICON plc, IQVIA; in AI-medical-imaging: Brainomix (AIM:BOX) — also UK small-cap specialist.

Investment thesis

  • Genuine AI in medical imaging with paying customers — IXI™ is not press-release AI: hundreds of thousands of scans processed, 53% gross margin, validated platform now in v10. The Medidata commercial collaboration (used in 80% of FDA novel approvals) is real third-party validation 2026-05-19 H1.
  • Operating leverage inflection visible — Revenue +23% YoY drove gross margin from 49.6% to 53.2% in H1 26 with EBITDA loss narrowing from £0.7m to £0.5m; the cost base is largely fixed (scientists, platform), so incremental revenue should drop disproportionately to profit. Management guidance to break-even at ~£8m revenue 2024-10-08 placing implies near-term inflection plausible.
  • Valuation distress vs. cash + order book — At 8.65p, market cap £18.9m is barely above ~£11m net cash, implying ~£8m EV for a business with £18.1m contracted order book covering 95% of FY26 expectations 2026-05-19 H1. The new placing at 8p (premium to prior close) was oversubscribed and backed by Octopus and Gresham House 2026-03-31 placing.

Key risks

  • Persistent dilution and equity funding dependence — Two capital raises in 18 months (Oct 2024 £3.7m net; April 2026 £9.4m net), share count up from 48m to 218m — a 4.5x expansion. Continued losses + investment in TechBio strategy may require further raises 2026-03-31 placing; 2024-10-08 placing.
  • Customer concentration and trial cancellation history — Track record includes two major client trial cessations (March 2021, January 2022) that materially descoped the order book. Pharma R&D cycles and biotech funding remain unpredictable 2024-05-21 H1; 2022-05-24 H1.
  • TechBio strategy execution risk — The £10m raise is explicitly for an unproven pivot (platform licensing, FDA SaMD approval). Management's premise that this attracts 4-7x revenue multiples is speculative; if licensing revenue doesn't materialise, the business remains a sub-scale iCRO at 1-3x revenue 2026-03-31 placing.

Operating leverage

The H1 26 results illustrate the leverage in stark form: revenue +23% (£3.9m vs £3.2m) drove gross profit +31% (£2.1m vs £1.6m) while the operating expense base grew only ~19% (£3.3m vs £2.8m). Gross margin moved 360bps to 53.2%; management explicitly notes "the relatively fixed nature of IXICO's costs of delivery" 2026-05-19 H1. With ~80 employees (~50%+ of cost base) and a fixed-cost cloud platform, an additional 10-20% revenue beat above the ~£7.5m FY26 trajectory could close most of the £1.3m FY25 EBITDA loss, given that incremental gross profit would land at 55-60%+ on largely flat operating expense. The 2024 placing circular flagged ~£8m revenue as the break-even threshold 2024-10-08 placing. Above that point, contribution margin compounding suggests EBIT could exit a £10m revenue run-rate with mid-teens EBITDA margins — a multi-bagger of profit per pound of incremental revenue.

Value-trap signals

  • Repeated rescue capital raises at progressively lower share prices — Oct 2024 at 9.5p; April 2026 at 8p — diluted base ~4.5x in 18 months, suggests structural inability to self-fund growth.
  • Loss-making for the entire period covered by these filings (FY22 was the only EBITDA-positive year at £1.5m, since reversed).
  • Client/trial concentration risk has materialised twice in the period (HD trial cessations 2021 and 2022) — not idiosyncratic, structural to small CRO.
  • Going-concern language softening but persistent investment phase — even with £11m cash, business plan calls for cash burn into FY27 to fund TechBio.

Earnings vs. expectations

Across the period, performance vs. guidance has been mixed but improving recently. The March 2024 trading update was a clear miss/profit warning (FY24 revenue cut to £5.2–5.9m from prior expectations) due to contract delays 2024-03-13. The August 2024 update upgraded to £5.5–5.9m, and FY24 delivered £5.8m — in line with revised guidance 2024-08-14. FY25 trading updates progressively beat expectations (July 2025 raised to ≥£6.3m; October 2025 actual £6.5m, "exceeded market expectations") 2025-07-17; 2025-10-16. H1 26 came in 23% YoY, in line with the April pre-close update 2026-04-21; 2026-05-19. Pattern: a profit warning in early 2024 followed by a consistent run of in-line/beat results under new CEO Bram Goorden — more beats than misses recently, but the longer record includes the 2021/2022 trial-cessation shocks.

Conviction

3/5 — moderate.

Anchors: (1) clean and timely AIM disclosure with detailed order book and cash bridges; (2) reasonable visibility from £18.1m contracted order book (95% of FY26 mkt expectation); (3) multiple converging valuation approaches (EV/revenue, sum-of-parts, cash floor) all suggest the stock is undervalued at the current price.

Limits: (1) loss-making business — DCF is not robust and any fair value rests on a revenue-multiple assumption that ranges from 1.5x to 4x; (2) the TechBio licensing pivot is genuinely binary — execution success could double the multiple, failure leaves them as a sub-scale CRO trading on cash + 1.5x revenue, which is barely above today's price.

Driver scoring summary

The company merits a medium AI score: it is a genuine AI-in-medical-imaging business with paying biopharma customers, but it is itself spending heavily on AI platform development and the value-capture from "agentic AI" diffusion doesn't obviously accrue to a sub-scale specialist CRO. High operating leverage given fixed cost base and software platform. The valuation is genuinely discounted vs. the strategy. Downside is moderated by ~£11m net cash but the loss profile and dilution history are real fragilities.

Overall score: 480 — partial fit. Strong on operating leverage and valuation, moderate on AI alignment, weak on quality/dilution history.

Filings consulted · 36

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-05-19Interim Results For Six Months Ending 31 03 20262026-05-19_9574199_interim-results-for-six-months-ending-31-03-2026.md0.90
  2. 2026-04-21Trading Update2026-04-21_9529275_trading-update.md0.85
  3. 2026-03-31Placings And Subscription2026-03-31_9499214_placings-and-subscription.md0.70
  4. 2025-11-27Notice OF 2025 Full Year Results And Imc2025-11-27_9260022_notice-of-2025-full-year-results-and-imc.md0.85
  5. 2025-11-03Capital Markets Day Presentation And Video2025-11-03_9209527_capital-markets-day-presentation-and-video.md0.81
  6. 2025-10-16Trading Update2025-10-16_9173985_trading-update.md0.72
  7. 2025-09-30Notice OF Capital Markets Day2025-09-30_9138710_notice-of-capital-markets-day.md0.81
  8. 2025-07-17Trading Update2025-07-17_8983374_trading-update.md0.72
  9. 2025-05-20Half Year Report2025-05-20_8886239_half-year-report.md0.58
  10. 2025-05-06Notice OF Interim Results Amp Investor Presentation2025-05-06_8861130_notice-of-interim-results-amp-investor-presentation.md0.58
  11. 2025-04-16Trading Update2025-04-16_8833226_trading-update.md0.55
  12. 2025-01-24Result OF Agm2025-01-24_8705699_result-of-agm.md0.20
  13. 2024-11-25Notice OF Results And Investor Presentation2024-11-25_8569469_notice-of-results-and-investor-presentation.md0.46
  14. 2024-10-09Result OF Placing And Subscription2024-10-09_8474274_result-of-placing-and-subscription.md0.46
  15. 2024-10-08Placing And Subscription2024-10-08_8473314_placing-and-subscription.md0.46
  16. 2024-08-14Trading Update2024-08-14_8365393_trading-update.md0.55
  17. 2024-05-21Half Year Report2024-05-21_8209847_half-year-report.md0.41
  18. 2024-05-07Notice OF Half Year Results2024-05-07_8177508_notice-of-half-year-results.md0.41
  19. 2024-03-13Trading Update2024-03-13_8084675_trading-update.md0.38
  20. 2024-01-25Result OF Agm2024-01-25_8007186_result-of-agm.md0.14
  21. 2023-11-27Notice OF Results And Investor Presentation2023-11-27_7903722_notice-of-results-and-investor-presentation.md0.32
  22. 2023-09-29Trading Update2023-09-29_7785460_trading-update.md0.38
  23. 2023-05-23Half Year Report2023-05-23_7538087_half-year-report.md0.23
  24. 2023-05-10Trading Update2023-05-10_7519430_trading-update.md0.21
  25. 2023-02-07Trading Update2023-02-07_7400070_trading-update.md0.21
  26. 2023-01-27Result OF Agm2023-01-27_7232425_result-of-agm.md0.07
  27. 2022-11-21Notice OF Results And Investor Presentation2022-11-21_7418878_notice-of-results-and-investor-presentation.md0.17
  28. 2022-10-25Trading Update2022-10-25_7156716_trading-update.md0.21
  29. 2022-09-01Trading Update And Fy2023 Guidance2022-09-01_7163379_trading-update-and-fy2023-guidance.md0.21
  30. 2022-05-24Half Year Report And Trading Update2022-05-24_6975141_half-year-report-and-trading-update.md0.23
  31. 2022-05-16Investor Presentation2022-05-16_6890846_investor-presentation.md0.17
  32. 2022-04-25Trading Update2022-04-25_7039598_trading-update.md0.21
  33. 2022-01-20Result OF Agm2022-01-20_6910922_result-of-agm.md0.07
  34. 2021-10-18Trading Update For Year Ended 30 September 20212021-10-18_6814900_trading-update-for-year-ended-30-september-2021.md0.21
  35. 2021-08-06Trading Update2021-08-06_6440458_trading-update.md0.21
  36. 2021-05-25Half Yearly Report TO 31 March 20212021-05-25_6482680_half-yearly-report-to-31-march-2021.md0.09

This research note was authored by a large language model after reading 33 regulatory filings published between 2021-05-25 and 2026-05-19. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.